文献速递关节外科运动医学

机器人臂辅助髌股关节置换术的生存率与患者报告结局及可接受症状状态阈值

Survival and patient-reported outcomes of robotic arm-assisted patellofemoral arthroplasty and patient-acceptable symptom state thresholds : a multicentre retrospective cohort study with minimum one-year follow-up.
PubMed 文献 · Bone Joint J · 2026-02-01

这项多中心回顾性队列研究纳入112例机器人臂辅助髌股关节置换术(raPFA),平均随访3.3年。四年全因再手术生存率为94.4%,全因翻修生存率为96.7%,无菌性翻修生存率为97.7%。约五分之一患者不满意, dissatisfaction与ASA分级升高独立相关;研究定义了OKS、Kujala、EQ-5D和EQ-VAS的PASS阈值。

要点

  • raPFA四年全因再手术生存率94.4%,全因翻修生存率96.7%。
  • 满意度77.9%,NPS为59.7,约五分之一患者不满意。
  • ASA分级升高与不满意独立相关(OR 0.02,95%CI 0.00-0.22,p=0.001)。

核心结论

  • raPFA与有临床意义的术后结局指标和高NPS相关,但约五分之一患者不满意,约二十分之一在术后前四年接受再手术。
  • 研究定义的PFA专用PASS阈值可用于未来研究中的结局解读。

研究设计与样本

  • 多中心回顾性队列研究,纳入112例机器人臂辅助髌股关节置换术(raPFA)。
  • 患者平均年龄63.3岁(范围21-89),女性88例(78.6%),平均随访3.3年(范围1.0-7.7)。

主要发现

  • 随访期间共4例再手术(其中3例翻修)。
  • 四年全因再手术生存率94.4%(95%CI 89.9-98.9),全因翻修生存率96.7%(95%CI 94.5-100),无菌性翻修生存率97.7%(95%CI 93.8-100)。
  • OKS、Kujala、EQ-5D和EQ-VAS的PASS达成率分别为76.0%(79例)、59.6%(62例)、64.4%(67例)和54.4%(49例)。
  • 满意度77.9%(81例),NPS为59.7。
  • ASA分级升高与不满意独立相关(OR 0.02,95%CI 0.00-0.22,p=0.001)。

关键数值与推荐

  • OKS的PASS阈值为36,Kujala为72,EQ-5D为0.710,EQ-VAS为74。
  • OKS的AUC为89.1(95%CI 82.5-95.8),Kujala为86.1(95%CI 77.7-94.5),EQ-5D为75.4(95%CI 61.7-89.1),EQ-VAS为76.7(95%CI 64.0-89.5)。
  • 使用新阈值后,OKS的PASS达成例数降至75例(72.1%),Kujala升至73例(70.2%),EQ-VAS升至58例(64.4%),EQ-5D不变。

临床怎么用

  • raPFA术后多数患者可获得有临床意义的改善和高推荐度,但需告知约五分之一不满意及约二十分之一再手术的风险。
  • 合并症负担较重(ASA分级升高)的患者不满意风险更高,围手术期应加强评估与沟通。
  • OKS和Kujala对满意度的区分能力优良,EQ-5D和EQ-VAS可接受,可用于临床结局评估。

局限性

  • 本研究为回顾性队列设计,可能存在选择偏倚和未测量混杂。
  • 平均随访3.3年,部分患者随访时间较短,长期生存率和结局尚需更长时间验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to assess the implant survival and patient-reported outcome measures of robotic arm-assisted patellofemoral arthroplasty (raPFA) and to define patient-acceptable symptom state (PASS) thresholds. METHODS: A multicentre retrospective cohort study of 112 raPFA was undertaken. The mean age of the patients was 63.3 years (21 to 89), and 88 (78.6%) were female. Oxford Knee Score (OKS), Kujala score, EuroQol five-dimension questionnaire (EQ-5D), EuroQol-visual analogue scale (EQ-VAS), Net Promoter Score (NPS), and patient satisfaction were assessed. Mean follow-up was 3.3 years (1.0 to 7.7). RESULTS: There were four reoperations (three revisions) during the follow-up period. The four-year survival was 94.4% (95% CI 89.9 to 98.9) for all-cause reoperation, 96.7% (95% CI 94.5 to 100) for all-cause revision, and 97.7% (95% CI 93.8 to 100) for aseptic revision. A total of 79 (76.0%), 62 (59.6%), 67 (64.4%), and 49 (54.4%) knees achieved the PASS thresholds in the OKS, Kujala, EQ-5D, and EQ-VAS scores, respectively. The satisfaction rate was 77.9% (n = 81) and the NPS was 59.7. Increasing American Society of Anesthesiologists (ASA) grade (odds ratio 0.02, 95% CI 0.00 to 0.22, p = 0.001) was independently associated with dissatisfaction. The OKS (area under the curve (AUC) 89.1, 95% CI 82.5 to 95.8) and Kujala score (AUC 86.1, 95% CI 77.7 to 94.5) were excellent, and the EQ-5D (AUC 75.4, 95% CI 61.7 to 89.1) and EQ-VAS (AUC 76.7, 95% CI 64.0 to 89.5) were acceptable discriminators of satisfaction, with PASS thresholds of 36, 72, 0.710, and 74, respectively. Using these new thresholds, the number achieving a PASS decreased in the OKS (n = 75; 72.1%), increased in the Kujala score (n = 73; 70.2%) and EQ-VAS (n = 58; 64.4%), and remained identical for the EQ-5D. CONCLUSION: raPFA was associated with clinically meaningful postoperative outcome measures and a high NPS. However, approximately one in five were not satisfied, which was independently associated with increasing comorbidity, and approximately one in 20 underwent reoperation in the first four years postoperatively. The defined PASS thresholds specifically for PFA could be used to help interpret outcomes in future studies.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Clement ND, Patton JT, Ohly NE, et al. Survival and patient-reported outcomes of robotic arm-assisted patellofemoral arthroplasty and patient-acceptable symptom state thresholds : a multicentre retrospective cohort study with minimum one-year follow-up. Bone Joint J. 2026. PMID: 41619763. doi:10.1302/0301-620X.108B2.BJJ-2025-0439.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。